Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptasel1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus
NEWS	18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:23:41 ON 20 JAN 2010

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 13:23:52 ON 20 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2010 HIGHEST RN 1202629-39-7
DICTIONARY FILE UPDATES: 19 JAN 2010 HIGHEST RN 1202629-39-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10571264.str



chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 8-10
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-3 2-7 3-9 5-11 7-8 8-9 8-10
normalized bonds :
1-2 1-6 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:24:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   9126 TO ITERATE

 21.9% PROCESSED   2000 ITERATIONS   50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 176793 TO   188247
PROJECTED ANSWERS: 6323 TO   8643

L2   50 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 13:24:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   183690 TO ITERATE

100.0% PROCESSED   183690 ITERATIONS   7659 ANSWERS
SEARCH TIME: 00.00.05

L3   7659 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   191.54   191.76

FILE 'CAPLUS' ENTERED AT 13:24:26 ON 20 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
FILE COVERS 1907 - 20 Jan 2010  VOL 152 ISS 4
FILE LAST UPDATED: 19 Jan 2010  (20100119/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Oct 2009
```

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4         974 L3

=> fil reg
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.50     192.26

FILE 'REGISTRY' ENTERED AT 13:24:34 ON 20 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES:   19 JAN 2010  HIGHEST RN 1202629-39-7
DICTIONARY FILE UPDATES:  19 JAN 2010  HIGHEST RN 1202629-39-7
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\STNEXP\Queries\10517264b.str



chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 8-10
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 5-11 7-8 8-9 8-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 13:25:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9126 TO ITERATE

21.9% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       176793 TO   188247
PROJECTED ANSWERS:            6323 TO     8643

L6           50 SEA SSS SAM L5

=> s l5 ful
FULL SEARCH INITIATED 13:25:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   183690 TO ITERATE

100.0% PROCESSED   183690 ITERATIONS                              7659 ANSWERS
SEARCH TIME: 00.00.05

L7         7659 SEA SSS FUL L5

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     191.54     383.80

FILE 'CAPLUS' ENTERED AT 13:25:19 ON 20 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 20 Jan 2010  VOL 152 ISS 4
FILE LAST UPDATED: 19 Jan 2010  (20100119/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Oct 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l7
L8           974 L7

=> s l8 and benzimidazole
          27787 BENZIMIDAZOLE
           6678 BENZIMIDAZOLES
          29310 BENZIMIDAZOLE
                (BENZIMIDAZOLE OR BENZIMIDAZOLES)
L9           232 L8 AND BENZIMIDAZOLE

=> s l9 and pentanoate
```

```
          2028 PENTANOATE
            86 PENTANOATES
          2085 PENTANOATE
                 (PENTANOATE OR PENTANOATES)
L10          0 L9 AND PENTANOATE

=> s l8 and benzimidazole-2-one-5-n-pentanoate
         27787 BENZIMIDAZOLE
          6678 BENZIMIDAZOLES
         29310 BENZIMIDAZOLE
                 (BENZIMIDAZOLE OR BENZIMIDAZOLES)
      10376058 2
       2973104 ONE
        211805 ONES
       3138602 ONE
                 (ONE OR ONES)
       7229365 5
       3410058 N
          2028 PENTANOATE
            86 PENTANOATES
          2085 PENTANOATE
                 (PENTANOATE OR PENTANOATES)
             0 BENZIMIDAZOLE-2-ONE-5-N-PENTANOATE
                 (BENZIMIDAZOLE(W)2(W)ONE(W)5(W)N(W)PENTANOATE)
L11          0 L8 AND BENZIMIDAZOLE-2-ONE-5-N-PENTANOATE

=> s l9 and mif
          2981 MIF
            83 MIFS
          3015 MIF
                 (MIF OR MIFS)
L12          3 L9 AND MIF

=> d ibib abs hitstr tot
```

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:705477 CAPLUS
DOCUMENT NUMBER: 147:110220
TITLE: MIF inhibitors
INVENTOR(S): Morand, Eric Francis; Skene, Colin Edward; Tapley, Peter Mark; Li, Xinhua; Jozefiak, Thomas H.
PATENT ASSIGNEE(S): Cortical Pty Ltd, Australia
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070961	A1	20070628	WO 2006-AU1965	20061221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006326850	A1	20070628	AU 2006-326850	20061221
CA 2634212	A1	20070628	CA 2006-2634212	20061221
EP 1968576	A1	20080917	EP 2006-840387	20061221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009521415	T	20090604	JP 2008-546033	20061221
ZA 2008005386	A	20090429	ZA 2008-5386	20080620
IN 2008KN02589	A	20090123	IN 2008-KN2589	20080625
KR 2008090435	A	20081008	KR 2008-717792	20080721
CN 101410107	A	20090415	CN 2006-80053213	20080821
US 20090130165	A1	20090521	US 2008-158563	20081223

PRIORITY APPLN. INFO.: US 2005-752354P P 20051221
WO 2006-AU1965 W 20061221
WO 2006-US1965 W 20061221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 147:110220

AB The present invention relates to the use of specific benzimidazolone analogs and derivs. to inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biol. activity is implicated. Novel benzimidazole analogs and derivs. are also provided.

IT 942609-74-7P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MIF inhibitors)
RN 942609-74-7 CAPLUS
CN Acetic acid, 2-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



IT 942609-71-4P 942609-72-5P 942609-73-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MIF inhibitors)
RN 942609-71-4 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]-, methyl ester (CA INDEX NAME)



RN 942609-72-5 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-73-6 CAPLUS
CN Acetic acid, 2-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]-, methyl ester (CA INDEX NAME)



IT 942609-75-8P 942609-78-1P 942609-90-7P
942609-91-8P 942609-92-9P 942609-93-0P
942609-94-1P 942609-95-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MIF inhibitors)
RN 942609-75-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[2-[(2-hydroxyethyl)thio]acetyl]- (CA INDEX NAME)



RN 942609-78-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[2-[(6-hydroxyhexyl)thio]acetyl]- (CA INDEX NAME)



RN 942609-90-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-6-chloro-1,3-dihydro- (CA INDEX NAME)



RN 942609-91-8 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 942609-93-0 CAPLUS
CN Propanoic acid, 3-[[2-(6-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-94-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-6-chloro-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 942609-95-2 CAPLUS
CN Propanoic acid, 3-[[2-(6-chloro-2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



IT 93202-41-6P 93202-51-8P 897545-61-8P
897545-85-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(MIF inhibitors)
RN 93202-41-6 CAPLUS

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN 2H-Benzimidazol-2-one, 5-(2-chloroacetyl)-1,3-dihydro- (CA INDEX NAME)



RN 93202-51-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro- (CA INDEX
NAME)



RN 897545-61-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-(2-chloroacetyl)-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 897545-85-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 634602-82-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, pentyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:567119 CAPLUS
DOCUMENT NUMBER: 143:83496
TITLE: Implantable device containing inhibitor of macrophage migration inhibitory factor
INVENTOR(S): Morand, Eric Francis; Iskander, Magdy Naguib; Skene, Colin Edward; Tapley, Peter Mark
PATENT ASSIGNEE(S): Cortical Pty Ltd., Australia
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058304	A1	20050630	WO 2004-AU1778	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			AU 2003-906983	A 20031217

OTHER SOURCE(S): MARPAT 143:83496
AB The present invention provides an implantable device, particularly a stent, comprising: (i) a reservoir containing at least one MIF inhibitor; and (ii) means to release or elute the inhibitor from the reservoir. Also disclosed are methods of treatment of diseases associated
with MIF cytokine activity using the implantable device. Treatment with pentyl 2-oxo-2,3-dihydro-1H-1,3-benzimidazole -5-carboxylate significantly inhibited vascular smooth muscle cell survival and proliferation.
IT 23814-14-4 36896-32-9 634602-82-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(implantable device containing inhibitor of macrophage migration inhibitory
factor)
RN 23814-14-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 36896-32-9 CAPLUS
CN 1H-Benzimidazole-5-butanoic acid, 2,3-dihydro-γ,2-dioxo- (CA INDEX NAME)

L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:991486 CAPLUS
DOCUMENT NUMBER: 140:27827
TITLE: Preparation of benzimidazole derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
INVENTOR(S): Morand, Eric Francis; Iskander, Magdy Naguib
PATENT ASSIGNEE(S): Cortical Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104203	A1	20031218	WO 2003-AU717	20030606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487838	A1	20031218	CA 2003-2487838	20030606
AU 2003233244	A1	20031222	AU 2003-233244	20030606
GB 2405147	A	20050223	GB 2004-27242	20030606
GB 2405147	B	20061122		
EP 1511736	A1	20050309	EP 2003-727010	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675185	A	20050928	CN 2003-818935	20030606
JP 2005533049	T	20051104	JP 2004-511273	20030606
NZ 537301	A	20060630	NZ 2003-537301	20030606
IN 2004KN01848	A	20060804	IN 2004-KN1848	20041206
ZA 2004009845	A	20060927	ZA 2004-9845	20041206
US 20060154977	A1	20060713	US 2005-517264	20050930
PRIORITY APPLN. INFO.:			AU 2002-2832	A 20020607
			AU 2002-2834	A 20020607
			WO 2003-AU717	W 20030606

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:27827
GI



I

AB Title compds. I [X = O, S, alkyl, amino; Y = amino, O, S, alkyl; Z = CO, CS, imino, SO, SO2; R1 = H, alkyl, alkyloxy, etc.; R2 = alkyl, alkenyl, alkynyl, etc.; R3 = H, alkyl, alkylamino, alkylalkoxy, etc.; R4 = H, halo, alkyl, alkenyl, alkynyl, etc.] are prepared For instance, 3,4-diaminotoluene is reacted with urea (pentanol, reflux) to give 5-methylbenzimidazol-2-one (56%). Example compds. are inhibitors of the cytokine or biol. activity of macrophage migration inhibitory factor (MIF). I are useful for the treatment of Lyme disease, connective tissue diseases, etc.

IT 5400-75-9P 23814-14-4P 67014-36-2P
83573-62-0P 634602-85-0P 634602-87-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzimidazoles which inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF))

RN 5400-75-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-methyl- (CA INDEX NAME)



RN 23814-14-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 67014-36-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-amino-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 83573-62-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-methyl-6-nitro- (CA INDEX NAME)



RN 634602-85-0 CAPLUS
CN L-Serine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-87-2 CAPLUS
CN L-Phenylalanine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 36896-35-2P 100253-32-5P 106429-57-6P
634602-82-7P 634602-83-8P 634602-84-9P
634602-86-1P 634602-88-3P 634602-89-4P
634602-91-8P 634602-92-9P 634602-93-0P
634602-94-1P 634602-95-2P 634602-96-3P
634602-97-4P 634603-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(prepn. of substituted benzimidazoles which inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF))

RN 36896-35-2 CAPLUS
CN 1H-Benzimidazole-5-pentanoic acid, 2,3-dihydro-δ,2-dioxo- (CA INDEX NAME)



RN 100253-32-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-pentyl- (CA INDEX NAME)



RN 106429-57-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, methyl ester (CA INDEX NAME)



RN 634602-82-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, pentyl ester (CA INDEX NAME)



RN 634602-83-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, 2-(2-hydroxyethoxy)ethyl ester (CA INDEX NAME)



RN 634602-84-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)



RN 634602-86-1 CAPLUS
CN L-Serine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-88-3 CAPLUS
CN L-Phenylalanine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-89-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-(3,4-dihydroxyphenyl)ethyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 634602-91-8 CAPLUS
CN β-D-Glucopyranose, 2,3,4,6-tetraacetate
1-(2,3-dihydro-2-oxo-1H-benzimidazole-5-carboxylate) (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-bromo-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 634602-93-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-hydroxy-6-methyl- (CA INDEX NAME)



RN 634602-94-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-tridecyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 634602-95-2 CAPLUS
CN 2H-Benzimidazol-2-one, 4,5,7-tribromo-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 634602-96-3 CAPLUS
CN Acetamide, N-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-5-yl)-2-(2-pyrimidinylthio)- (CA INDEX NAME)



RN 634602-97-4 CAPLUS
CN 1H-Benzimidazole-5-carbothioic acid, 2,3-dihydro-2-oxo-, S-pentyl ester (CA INDEX NAME)



RN 634603-00-2 CAPLUS
CN 1H-Benzimidazole-5-carboximidamide, N-butyl-2,3-dihydro-2-oxo- (CA INDEX NAME)

```
=> s l9 and glucocorticoid
          36484 GLUCOCORTICOID
          28642 GLUCOCORTICOIDS
          45917 GLUCOCORTICOID
                  (GLUCOCORTICOID OR GLUCOCORTICOIDS)
L13           4 L9 AND GLUCOCORTICOID

=> d ibib abs hitstr tot
```

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:705477 CAPLUS
DOCUMENT NUMBER: 147:110220
TITLE: MIF inhibitors
INVENTOR(S): Morand, Eric Francis; Skene, Colin Edward; Tapley, Peter Mark; Li, Xinhua; Jozefiak, Thomas H.
PATENT ASSIGNEE(S): Cortical Pty Ltd, Australia
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070961	A1	20070628	WO 2006-AU1965	20061221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006326850	A1	20070628	AU 2006-326850	20061221
CA 2634212	A1	20070628	CA 2006-2634212	20061221
EP 1968576	A1	20080917	EP 2006-840387	20061221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009521415	T	20090604	JP 2008-546033	20061221
ZA 2008005386	A	20090429	ZA 2008-5386	20080620
IN 2008KN02589	A	20090123	IN 2008-KN2589	20080625
KR 2008090435	A	20081008	KR 2008-717792	20080721
CN 101410107	A	20090415	CN 2006-80053213	20080821
US 20090130165	A1	20090521	US 2008-158563	20081223

PRIORITY APPLN. INFO.: US 2005-752354P P 20051221
WO 2006-AU1965 W 20061221
WO 2006-US1965 W 20061221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 147:110220

AB The present invention relates to the use of specific benzimidazolone analogs and derivs. to inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biol. activity is implicated. Novel benzimidazole analogs and derivs. are also provided.

IT 942609-74-7P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MIF inhibitors)
RN 942609-74-7 CAPLUS
CN Acetic acid, 2-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



IT 942609-71-4P 942609-72-5P 942609-73-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MIF inhibitors)
RN 942609-71-4 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]-, methyl ester (CA INDEX NAME)



RN 942609-72-5 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-73-6 CAPLUS
CN Acetic acid, 2-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]-, methyl ester (CA INDEX NAME)



IT 942609-75-8P 942609-78-1P 942609-90-7P
942609-91-8P 942609-92-9P 942609-93-0P
942609-94-1P 942609-95-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MIF inhibitors)
RN 942609-75-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[2-[(2-hydroxyethyl)thio]acetyl]- (CA INDEX NAME)



RN 942609-78-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[2-[(6-hydroxyhexyl)thio]acetyl]- (CA INDEX NAME)



RN 942609-90-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-6-chloro-1,3-dihydro- (CA INDEX NAME)



RN 942609-91-8 CAPLUS
CN Propanoic acid, 3-[[2-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 942609-93-0 CAPLUS
CN Propanoic acid, 3-[[2-(6-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



RN 942609-94-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-6-chloro-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 942609-95-2 CAPLUS
CN Propanoic acid, 3-[[2-(6-chloro-2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-oxoethyl]thio]- (CA INDEX NAME)



IT 93202-41-6P 93202-51-8P 897545-61-8P
897545-85-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(MIF inhibitors)
RN 93202-41-6 CAPLUS

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN 2H-Benzimidazol-2-one, 5-(2-chloroacetyl)-1,3-dihydro- (CA INDEX NAME)



RN 93202-51-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro- (CA INDEX
NAME)



RN 897545-61-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-(2-chloroacetyl)-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 897545-85-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:269508 CAPLUS
DOCUMENT NUMBER: 144:331420
TITLE: Preparation of bicyclic anilide spirolactam cgrp receptor antagonists
INVENTOR(S): Bell, Ian M.; Theberge, Cory R.; Stump, Craig A.; Zhang, Xufang; Gallicchio, Steven N.; Zartman, C. Blair
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031610	A2	20060323	WO 2005-US32041	20050909
WO 2006031610	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005285109	A1	20060323	AU 2005-285109	20050909
CA 2579847	A1	20060323	CA 2005-2579847	20050909
EP 1797073	A2	20070620	EP 2005-795448	20050909
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101018781	A	20070815	CN 2005-80030605	20050909
JP 2008512481	T	20080424	JP 2007-531342	20050909
IN 2007DN01493	A	20070803	IN 2007-DN1493	20070223
US 20080096878	A1	20080424	US 2007-662703	20070313

PRIORITY APPLN. INFO.: US 2004-609292P P 20040913
WO 2005-US32041 W 20050909

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 144:331420
GI

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



I



II

AB Title compds. I [A1 and A2 independently = bond or CR13R14, where one of A1 and A2 is optionally absent; B = (un)substituted bicycloheterocycle; J = =C(R6a)-; CR13R14, and CO; K = =C(R6b), CR13R14, CO, etc.; R4 = H, (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy, halo, etc.; R6a and R6b independently = H, OH, halo, (un)substituted alkyl, etc.; R13 and R14 = H or (un)substituted alkyl; m = 1 or 2; n = 1 or 2], and their pharmaceutically acceptable salts, useful as antagonists of calcitonin gene-related peptide (CGRP) receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. Thus, e.g., II was prepared by reaction of 5-amino-1,3-dihydro-2'H,5'H-spiro[indene-2,3'-pyrrolidine]-2',5'-dione (preparation given) with 5-amino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one (preparation given). I demonstrated activity as antagonists of the CGRP receptor with Ki or IC50 values generally less than about 50 μM. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.
IT 880077-47-4P 880077-51-0P 880077-93-0P
880077-97-4P 880078-00-2P 880078-03-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic anilide spirolactam cgrp receptor antagonists)
RN 880077-47-4 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 3-[2-[(1,3-dihydro-2'-oxospiro[2H-indene-2,3'-pyrrolidin]-5-yl)amino]-2-oxoethyl]-2,3-dihydro-5,7-dimethyl-2-oxo-, methyl ester (CA INDEX NAME)

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 880077-51-0 CAPLUS
CN 1H-Benzimidazole-1,3(2H)-diacetamide,
N1-(1,3-dihydro-2'-oxospiro[2H-indene-2,3'-pyrrolidin]-5-yl)-4,6-dimethyl-2-oxo- (CA INDEX NAME)



RN 880077-93-0 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-5,7-dimethyl-2-oxo-3-[2-oxo-2-[(1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl)amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 880077-97-4 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-5,7-dimethyl-2-oxo-3-[2-oxo-2-[(1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl)amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 880078-00-2 CAPLUS
CN 1H-Benzimidazole-1,3(2H)-diacetamide, N3,N3,4,6-tetramethyl-2-oxo-N1-(1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl)- (9CI) (CA INDEX NAME)



RN 880078-03-5 CAPLUS
CN 1H-Benzimidazole-1,3(2H)-diacetamide, N1,N1,4,6-tetramethyl-2-oxo-N3-(1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl)- (9CI) (CA INDEX NAME)



IT 102308-68-9P 767304-80-3P 767304-81-4P
767304-82-5P 880079-11-8P 880079-13-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic anilide spirolactam cgrp receptor antagonists)

RN 102308-68-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-4,6-dimethyl- (CA INDEX NAME)



RN 767304-80-3 CAPLUS

CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-4,6-dimethyl-2-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 767304-81-4 CAPLUS
CN 1H-Benzimidazole-1,3(2H)-diacetic acid, 4,6-dimethyl-2-oxo-, 3-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)



RN 767304-82-5 CAPLUS
CN 1H-Benzimidazole-1,3(2H)-diacetic acid, 4,6-dimethyl-2-oxo-, 3-methyl ester (CA INDEX NAME)



RN 880079-11-8 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 3-[2-(dimethylamino)-2-oxoethyl]-2,3-dihydro-5,7-dimethyl-2-oxo- (CA INDEX NAME)



RN 880079-13-0 CAPLUS

CN 1H-Benzimidazole-1-acetic acid, 3-[2-(dimethylamino)-2-oxoethyl]-2,3-dihydro-5,7-dimethyl-2-oxo-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:991486 CAPLUS
DOCUMENT NUMBER: 140:27827
TITLE: Preparation of benzimidazole derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
INVENTOR(S): Morand, Eric Francis; Iskander, Magdy Naguib
PATENT ASSIGNEE(S): Cortical Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104203	A1	20031218	WO 2003-AU717	20030606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487838	A1	20031218	CA 2003-2487838	20030606
AU 2003233244	A1	20031222	AU 2003-233244	20030606
GB 2405147	A	20050223	GB 2004-27242	20030606
GB 2405147	B	20061122		
EP 1511736	A1	20050309	EP 2003-727010	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675185	A	20050928	CN 2003-818935	20030606
JP 2005533049	T	20051104	JP 2004-511273	20030606
NZ 537301	A	20060630	NZ 2003-537301	20030606
IN 2004KN01848	A	20060804	IN 2004-KN1848	20041206
ZA 2004009845	A	20060927	ZA 2004-9845	20041206
US 20060154977	A1	20060713	US 2005-517264	20050930

PRIORITY APPLN. INFO.: AU 2002-2832 A 20020607
AU 2002-2834 A 20020607
WO 2003-AU717 W 20030606

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:27827
GI



I

AB Title compds. I [X = O, S, alkyl, amino; Y = amino, O, S, alkyl; Z = CO, CS, imino, SO, SO2; R1 = H, alkyl, alkyloxy, etc.; R2 = alkyl, alkenyl, alkynyl, etc.; R3 = H, alkyl, alkylamino, alkylalkoxy, etc.; R4 = H, halo, alkyl, alkenyl, alkynyl, etc.] are prepared For instance, 3,4-diaminotoluene is reacted with urea (pentanol, reflux) to give 5-methylbenzimidazol-2-one (56%). Example compds. are inhibitors of the cytokine or biol. activity of macrophage migration inhibitory factor (MIF). I are useful for the treatment of Lyme disease, connective tissue diseases, etc.

IT 5400-75-9P 23814-14-4P 67014-36-2P
83573-62-0P 634602-85-0P 634602-87-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzimidazoles which inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF))

RN 5400-75-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-methyl- (CA INDEX NAME)



RN 23814-14-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 67014-36-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-amino-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 83573-62-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-methyl-6-nitro- (CA INDEX NAME)



RN 634602-85-0 CAPLUS
CN L-Serine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-87-2 CAPLUS
CN L-Phenylalanine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 36896-35-2P 100253-32-5P 106429-57-6P
634602-82-7P 634602-83-8P 634602-84-9P
634602-86-1P 634602-88-3P 634602-89-4P
634602-91-8P 634602-92-9P 634602-93-0P
634602-94-1P 634602-95-2P 634602-96-3P
634602-97-4P 634603-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(prepn. of substituted benzimidazoles which inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF))

RN 36896-35-2 CAPLUS
CN 1H-Benzimidazole-5-pentanoic acid, 2,3-dihydro-δ,2-dioxo- (CA INDEX NAME)



RN 100253-32-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-pentyl- (CA INDEX NAME)



RN 106429-57-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, methyl ester (CA INDEX NAME)



RN 634602-82-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, pentyl ester (CA INDEX NAME)



RN 634602-83-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, 2-(2-hydroxyethoxy)ethyl ester (CA INDEX NAME)



RN 634602-84-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)



RN 634602-86-1 CAPLUS
CN L-Serine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-88-3 CAPLUS
CN L-Phenylalanine, N-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-89-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-(3,4-dihydroxyphenyl)ethyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 634602-95-2 CAPLUS
CN 2H-Benzimidazol-2-one, 4,5,7-tribromo-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 634602-96-3 CAPLUS
CN Acetamide, N-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-5-yl)-2-(2-pyrimidinylthio)- (CA INDEX NAME)



RN 634602-97-4 CAPLUS
CN 1H-Benzimidazole-5-carbothioic acid, 2,3-dihydro-2-oxo-, S-pentyl ester (CA INDEX NAME)



RN 634603-00-2 CAPLUS
CN 1H-Benzimidazole-5-carboximidamide, N-butyl-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 634602-91-8 CAPLUS
CN β-D-Glucopyranose, 2,3,4,6-tetraacetate 1-(2,3-dihydro-2-oxo-1H-benzimidazole-5-carboxylate) (CA INDEX NAME)

Absolute stereochemistry.



RN 634602-92-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-bromo-1,3-dihydro-6-methyl- (CA INDEX NAME)



RN 634602-93-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-hydroxy-6-methyl- (CA INDEX NAME)



RN 634602-94-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-tridecyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:972178 CAPLUS
DOCUMENT NUMBER: 140:35946
TITLE: CFTR modifier genes and expressed proteins, in particular Kir4.2, and their regulators, useful in treating cystic fibrosis and methods and products for detecting and/or identifying same
INVENTOR(S): Whitsett, Jeffrey Allen; Aronow, Bruce Jefferson; Clark, Jean Cantwell
PATENT ASSIGNEE(S): Children's Hospital Medical Center, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003102140	A2	20031211	WO 2003-US16896	20030530
WO 2003102140	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488012	A1	20031211	CA 2003-2488012	20030530
AU 2003238791	A1	20031219	AU 2003-238791	20030530
EP 1513870	A2	20050316	EP 2003-734252	20030530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671734	A	20050921	CN 2003-818347	20030530
JP 2005528449	T	20050922	JP 2004-510382	20030530
US 20050158747	A1	20050721	US 2004-999587	20041130
PRIORITY APPLN. INFO.:			US 2002-384856P P	20020531
			US 2002-384855P P	20020531
			WO 2003-US16896 W	20030530

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to CFTR modifier genes, in particular the Kir4.2 gene, as well as their expressed proteins, that are useful in treating cystic fibrosis (CF), or at least the conditions that cause CF. It has been found that Kir4.2 able to compensate for the absence of CFTR. The Kir4.2 gene influences and potentiates chloride (Cl) ion transportation by providing potassium (K+) channel(s) as an alternative pathway(s). In addition, it has been found that the expressed polypeptide(s) of the Kir4.2 gene that provide these K+ channel(s) can be activated and/or regulated in response to various agents, such as cAMP stimulating agents (e.g., forskolin and IBMX) that stimulate Cl ion transportation via CFTR-dependent channels. Methods and products for detecting and/or identifying CFTR modifier genes, their resp. expressed polypeptides, the genetic regulators of such CFTR modifier genes, and the regulators of their resp. expressed polypeptides are disclosed. Also disclosed are compns. and methods using these CFTR modifier genes, their resp. expressed polypeptides, genetic regulators of these CFTR modifier genes, and/or CFTR modifier polypeptide regulators for the purpose of treating CF, or at least the conditions that cause CF, are disclosed.

IT 141797-92-4, NS 004
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NS 004; CFTR modifier genes and expressed proteins, in particular Kir4.2, and their regulators, useful in treating cystic fibrosis and methods and products for detecting and/or identifying same)
RN 141797-92-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-5-(trifluoromethyl)- (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      67.27     451.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.95      -5.95

STN INTERNATIONAL LOGOFF AT 13:29:47 ON 20 JAN 2010
```